http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3811949-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_268be9afa00cf55b5aa72b1612151ecb
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
filingDate 2019-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_987343007387d130aea06d6bd00168c6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82a4df40f58a77a05ebaea69cbf74623
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e09b4ef241f0feacbf43f5c93bc228a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76cb9dba3d445bfb0be3508a1aa03689
publicationDate 2021-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-3811949-A1
titleOfInvention Combined medicine comprising gemcitabine-encapsulated liposome composition and immune checkpoint blockade
abstract An object of the present invention is to provide a combined pharmaceutical formulation obtained by combining a liposome composition and an immune checkpoint inhibitor, in which gemcitabine is encapsulated in a dissolved state in liposomes in the liposome composition. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) an immune checkpoint inhibitor, in which the liposome composition includes liposomes each having an inner water phase, and an aqueous solution constituting an outer water phase and having the liposomes dispersed therein, gemcitabine is encapsulated in a dissolved state in the liposomes, and the liposome composition and the immune checkpoint inhibitor are administered simultaneously or sequentially.
priorityDate 2018-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395486
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60749
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6917
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226425662
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14985
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226414475
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID46705350
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396379
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396322
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226599064
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395359
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226401602
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6274
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID449005
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60750
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10908

Total number of triples: 46.